|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approved_drug
|
true
|
|
gptkbp:approvedBy
|
2001
|
|
gptkbp:ATCCode
|
L01EA01
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:CASNumber
|
152459-95-5
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
orphan drug
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:drugbank_ID
|
gptkb:DB00619
|
|
gptkbp:eliminationHalfLife
|
hepatic
18 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
gptkb:KHGXJUYNMMXHFG-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C29H31N7O
|
|
gptkbp:hasSMILES
|
CC1=CC=CC=C1NC(=O)C2=CC=CC=C2C3=NC=CC(=N3)N4CCN(CC4)C5=NC=CC=C5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ChEMBL651
|
|
gptkbp:indication
|
gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
493.6 g/mol
|
|
gptkbp:name
|
gptkb:Imatinib
|
|
gptkbp:patent
|
gptkb:US5521184A
|
|
gptkbp:pharmacology
|
inhibits BCR-ABL tyrosine kinase activity
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
CHEMBL651
5291
|
|
gptkbp:recipient
|
gptkb:PDGFRA
gptkb:KIT
gptkb:ABL1
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
edema
fatigue
rash
muscle cramps
|
|
gptkbp:structureType
|
small molecule
|
|
gptkbp:synonym
|
gptkb:Gleevec
gptkb:STI571
|
|
gptkbp:target
|
gptkb:BCR-ABL
gptkb:PDGFR
gptkb:c-Kit
|
|
gptkbp:toxicity
|
overdose may cause severe adverse effects
|
|
gptkbp:UNII
|
8CRO4J6NZF
|
|
gptkbp:bfsParent
|
gptkb:THC
|
|
gptkbp:bfsLayer
|
6
|